Page 11234..10..»


Category Archives: Hypogonadism

Erectile dysfunction: When he’s (not) in the mood for love – AsiaOne


Posted: December 4, 2019 at 11:46 am

Men are often portrayed as wanting to have sex all the time. In reality, a sluggish sex drive is something many men deal with at some point in their lives. Several studies, including the often-cited Massachusetts Male Ageing Study from the University of Boston (conducted between 1987 and 1989), suggest erectile dysfunction affects more than half of all men to some degree, and is more prevalent in older men Continue reading

Posted in Hypogonadism | Comments Off on Erectile dysfunction: When he’s (not) in the mood for love – AsiaOne

Expanded U.S. NATETSO Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational – Financial Post


Posted: December 4, 2019 at 11:46 am

TORONTO Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the revised commercial partnership agreement with Aytu Bioscience (Aytu) to accelerate the growth of NATESTO in the United States is now closed and fully effective as of December 1, 2019. Both parties have mutually waived the closing conditions of the revised partnership agreement, including the requirement that Acerus complete a raise of a minimum of USD 10 million on or before the end of January 2020, enabling Acerus to launch a U.S.-based specialty sales force, which will promote NATESTO to urologists and endocrinologists. Aytu will continue to book all NATESTO revenue in the United States and they will promote NATESTO to all other specialties including internal medicine and family practice. Continue reading

Posted in Hypogonadism | Comments Off on Expanded U.S. NATETSO Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational – Financial Post

Testosterone Replacement Therapy Market : Global Competitive Analytics and Insights 2016 2024 – Downey Magazine


Posted: November 29, 2019 at 8:54 pm

The global market for testosterone replacement therapy is characterized by the presence of a large number of small and large scale manufacturers. Continue reading

Posted in Hypogonadism | Comments Off on Testosterone Replacement Therapy Market : Global Competitive Analytics and Insights 2016 2024 – Downey Magazine

Testosterone Replacement Therapy Market to Expand at a Robust 4.20% CAGR Between 2016 and 2024 – Montana Ledger


Posted: November 25, 2019 at 7:45 pm

In a recent report by Transparency Market Research, it is shown that the global testosterone replacement therapy market is expected to grow negatively in the forecast period of 2016 to 2024. Continue reading

Posted in Hypogonadism | Comments Off on Testosterone Replacement Therapy Market to Expand at a Robust 4.20% CAGR Between 2016 and 2024 – Montana Ledger

Alex Nowbar’s weekly review22 November 2019 – The BMJ – The BMJ


Posted: November 24, 2019 at 4:50 pm

Alex Nowbar reviews the latest research from the top medical journals Annals of Internal Medicine Coaching for weight maintenance Conroy et al examine the role of coaching in weight management in a randomised controlled trial of 194 participants who had intentionally lost at least 5% of their body weight in the last two years. They also threw in a bit of electronic health records for good measure. The study arms were: tracking via electronic health records versus the same plus coaching Continue reading

Posted in Hypogonadism | Comments Off on Alex Nowbar’s weekly review22 November 2019 – The BMJ – The BMJ

Global and Regional M2M Platform Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 – Breaking News Updates


Posted: November 24, 2019 at 4:50 pm

The and Regional M2M Platform Market report gives a purposeful depiction of the area by the practice for research, amalgamation, and review of data taken from various sources. The market analysts have displayed the different sidelines of the area with a point on recognizing the top players (Gemalto, Jasper Technologies, Sierra Wireless, Telit Wireless Solutions, Xively, Amdocs, Digi International, Kore Wireless, PTC, Aeris, Bosch Software Innovations, Comarch, Cumulocity) of the industry. The and Regional M2M Platform market report correspondingly joins a predefined business market from a SWOT investigation of the real players Continue reading

Posted in Hypogonadism | Comments Off on Global and Regional M2M Platform Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 – Breaking News Updates

Human Chorionic Gonadotropin (HCG) Market 2019 By Share, Size, industry Trends, Outlook, Revenue, Manufacturers, Demand and Forecast to 2024 – Downey…


Posted: November 22, 2019 at 9:46 am

Human Chorionic Gonadotropin (HCG) Marketreport provides comprehensive insights, revenue generation information, and other significant information related to the global Human Chorionic Gonadotropin (HCG) market, as well as the different trends, drivers and restraints, opportunities, and threats in the parent market till 2024. Rise in the incidence of male hypogonadism among the geriatric population is the key factor driving the market growth. In addition, increase in traction gained by hCG among healthcare professionals and patients would supplement the market growth. Continue reading

Posted in Hypogonadism | Comments Off on Human Chorionic Gonadotropin (HCG) Market 2019 By Share, Size, industry Trends, Outlook, Revenue, Manufacturers, Demand and Forecast to 2024 – Downey…

Northland Securities Begins Coverage on Aytu Bioscience (NASDAQ:AYTU) – TechNewsObserver


Posted: November 22, 2019 at 9:46 am

Northland Securities started coverage on shares of Aytu Bioscience (NASDAQ:AYTU) in a research report released on Friday, November 15th, Stock Target Advisor reports. Continue reading

Posted in Hypogonadism | Comments Off on Northland Securities Begins Coverage on Aytu Bioscience (NASDAQ:AYTU) – TechNewsObserver

Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected…


Posted: November 21, 2019 at 1:45 am

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced results for one of the co-primary endpoints from CheckMate -915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo alone for the adjuvant treatment of patients who have had a complete surgical removal of stage IIIb/c/d or stage IV (no evidence of disease) melanoma. A statistically significant benefit was not reached for the co-primary endpoint of recurrence-free survival (RFS) in patients whose tumors expressed PD-L1 3 and up to 5 times the upper limit of normal (ULN), if AST/ALT is > 1 and up to 3 times ULN at baseline and increases to > 5 and up to 10 times the ULN, and if AST/ALT is > 3 and up to 5 times ULN at baseline and increases to > 8 and up to 10 times the ULN. Continue reading

Posted in Hypogonadism | Comments Off on Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected…

Mereo BioPharma And Leflutrozole In Hypogonadotropic …


Posted: October 11, 2019 at 10:51 am

Introduction Mereo BioPharma (MREO) is a British small-cap ($62M) biopharma developing therapeutics for rare disorders as well as endocrine and oncological diseases. MREO has a diverse pipeline including MPH-966 (alvelestat), BCT-197 (acumapimod), and OMP-305B83 (navicixizumab) for alpha-1 antitrypsin deficiency, chronic obstructive pulmonary disease, and ovarian cancer, respectively. The focus of this article is BGS-649 (leflutrozole), a drug asset licensed from Novartis (NVS) that is in clinical development for treating hypogonadotropic hypogonadism (Hypo-H) Continue reading

Posted in Hypogonadism | Comments Off on Mereo BioPharma And Leflutrozole In Hypogonadotropic …

Page 11234..10..»